US-based pharmaceutical giant Abbott is reportedly planning its latest acquisition, this time with Topera.
Reports say Abbott is seeking expansion through acquiring the medical device manufacturer; reports say the deal was inked for $250 million.
Abbott, like other pharmaceutical conglomerates across the globe, has lately looked to acquisitions to expand its reach. The company additionally announce that it has received regulatory approval to acquire Advanced Cardiac Therapeutics; financial details of this deal were not disclosed by the companies.
Abbott’s takeover of Topera will need to gain regulatory clearance before it moves forward.
Full content: MarketWatch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
EU Watchdog Mandates Boardroom Accountability for AI in Banks
May 30, 2024 by
CPI
Senate Democrats Urge DOJ Investigation into Alleged Big Oil Collusion
May 30, 2024 by
CPI
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI